Methods and compositions for engineered mitochondrial biogenesis
Patent Information
- Application Number
- PCT/US2024/022060
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-29
- Filing Date
- 2024-03-28
- Publication Date
- 2024-11-07
AI Technical Summary
Current methods for enhancing mitochondrial biogenesis in cells, such as cDNA overexpression and isolated mitochondria delivery, are inefficient and labor-intensive, failing to capture the functional diversity of mitochondrial isoforms and synergistic interactions among genes, leading to short-lived bioenergetic enhancements and scalability issues in clinical applications.
A method involving a fusion protein comprising a DNA-binding protein construct fused to a transcriptional regulator, specifically targeting and modulating endogenous genes like PPARGC1A, PPARGC1B, NRF1, and TFAM to increase mitochondrial activity, using CRISPR-Cas9 or zinc finger proteins for precise gene expression modulation, delivered via vectors like adeno-associated viral vectors or lipid nanoparticles.
This approach effectively and sustainably increases mitochondrial numbers and function in cells, offering a scalable and off-the-shelf solution for conditions like heart failure and wound healing, with enhanced bioenergetic benefits and reduced risk of pathological overexpression.
Smart Images

Figure US2024022060_07112024_PF_FP_ABST
Abstract
Description
[0001] DESCRIPTION METHODS AND COMPOSTIONS FOR ENGINEERED MITOCHONDRIAL BIOGENESIS STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT This invention was made with government support under grant no. 5R35GM143532 awarded by the National Institutes of Health. The government has certain rights in the invention. PRIORITY CLAIM This application claims benefit of priority to U.S. Provisional Application Serial No. 63 / 492,920, filed March 29, 2023, the entire contents of which are hereby incorporated by reference. SEQUENCE LISTING This application contains a Sequence Listing XML, which has been submitted electronically and is hereby incorporated by reference in its entirety. Said XML Sequence Listing, created on March 28, 2024, is named RICEP0123WO.xml and is 23,824 bytes in size. BACKGROUND 1. Field of the Disclosure The present disclosure relates generally to the fields of biogenesis, tissue engineering and regeneration and molecular biology. More particularly, the disclosure relates to engineered transcriptional activation systems that regulated endogenous gene expression to increase the number of mitochondria in cells. 2. Background Mitochondria are key organelles in human cellular energetics. A major interest of the medical community is the ability to control cellular mitochondria (Lightowlers et al., 2020; McCully et al., 2016). While generation of mitochondria has depended on cDNA expression vectors, it has become clear that many of the genes controlling mitochondrial biogenesis have
[0002] 14865-9395-0642, v. 1 multiple isoforms, each with different levels of cell type-dependent activity (De Virgilio et al., 2011; St-Pierre et al., 2003). Ischemic heart disease is the leading cause of death in the industrialized world, with nearly one third of patients developing heart failure (HF) after myocardial infarction (MI)(Benjamin et al., 2019; Velagaleti et al., 2008). An estimated 6.2 million Americans develop HF with a projected increase of 46% by 2030; moreover – heart failure currently results in 30 billion dollars in annual health care expenditures (Braunschweig et al., 2011; Heidenreich et al., 2013). A major component in the development of heart failure is insufficient energy supply, observed as a reduced mitochondrial capacity and altered cellular metabolism (Lopaschuk et al., 2021; Tian et al., 2019; Zhou & Tian, 2018; Taegtmeyer & Lubrano, 2014; Rosca et al., 2008; Neubauer, 2007; Lopaschuk et al., 2010; Ritterhoff & Tian, 2023). The normal adult heart generates enormous quantities of ATP via mitochondrial oxidative phosphorylation (95%) and glycolysis (5%) (Lopaschuk et al., 2021). Additionally, the normal heart is energetically adaptive, shifting between different energy substrates, such as fatty acids (40-60%), pyruvate, ketone bodies, and amino acids (Wilcox et al., 2015). However, the failing heart loses this energetic flexibility, shifting markedly towards glycolysis. This energetic shift is driven by both fewer and more dysfunctional mitochondria, which results in a 30% loss of ATP utilization in the heart (Lopaschuk et al., 2021; Tian et al., 2019; Wilcox et al., 2015). Therapeutic measures (beta- blockers and ace-inhibitors) to adjust the heart to the impaired energy supply through reduction of cardiac energy consumption can improve survival in HF (Doughty et al., 1994; SOLVD Investigators et al., 1991). However, these interventions become counterproductive over time because the reduction of cardiac energy results in additional pathologies, such as hypotension and bradycardia, and only address the demand side of energy imbalance. Conversely, new therapies focused on enhancing cardiac bioenergetics have produced promising therapeutic benefits. For example, resveratrol has been shown to restore mitochondrial function and reduce HF pathologies in mice (Lagouge et al., 2006; Sung et al., 2015; Wang et al., 2014). Unfortunately, these benefits have not been recapitulated in human clinical trials (Magyar et al., 2012; Zordoky et al., 2015), and this failure has been attributed to bioavailability challenges (Walle et al., 2004; Sung & Dyck, 2015). Therefore, the collective therapeutic landscape indicates that the precise manipulation and enhancement of cardiac bioenergetics is a powerful strategy to address HF subsequent to MI. The skin is one of the organs most susceptible to injury in part due to its surface area and protective nature. The U.S. is estimated to spend at least 30 billion dollars annually on
[0003] 24865-9395-0642, v. 1 wound care. The complex composition of the skin is a major factor in the wound healing process. Immediately after injury, various cell types, such as fibroblasts, keratinocytes, and stem cells, get activated in order to restore tissue homeostasis. Coordination between cells is mediated through signaling proteins and small molecules, particularly mitochondrial metabolites (Sen et al., 2002; Klyubin et al., 1996; Niethammer et al., 2009). These signals are pivotal in the wound healing process, as many key cellular processes, such as cell proliferation, migration, and differentiation, are tightly controlled by the cells due to their high energetic requirement. Ideally, the wound healing process results in regeneration, or complete functional restoration of the affected area. However, when cells at the injury site are unable to activate these processes efficiently, a fibrotic scar forms to patch the wound (Ting et al., 2005; Gurtner et al., 2008). While small injuries heal without major intervention, larger injuries often require medical intervention to heal properly. A standard of care for extensive wounds is hyperbaric oxygen therapy (HBOT). During HBOT, the wounds are exposed to 100% oxygen at above atmospheric pressure. This hyperoxic environment is thought to increase energy production at the tissue aiding in the reparative process (Rodriguez et al., 2008; Knighton et al., 1983; Soneja et al., 2005), yet broader implementation of the technique has been limited by costs and space constraints. Therefore, the therapeutic landscape indicates that the precise manipulation and enhancement of cellular bioenergetics is a powerful strategy to enhance the wound healing process. Due to the major role mitochondria play in cellular bioenergetics, they have been recognized as a valuable therapeutic target in heart failure (Tian et al., 2019; Zhou & Tian, 2018; Wang et al., 2016; Brown et al., 2017; Murphy et al., 2016). Increasing the quantity and function of mitochondria has been repeatedly shown to elicit positive therapeutic effects in the setting of HF, particularly with respect to heart function (Kaza et al., 2017; Guariento et al., 2021; Shin et al., 2019; Doulamis et al., 2020; Cowan et al., 2016; Masuzawa et al., 2013; McCully et al., 2009; Chatfield et al., 2019; Daubert et al., 2017; Brown et al., 2014; Sabbah et al., 2016). For instance, administration of autologous mitochondria via direct myocardial injection or intracoronary catheter delivery into animal models of HF (Kaza et al., 2017; Shin et al., 2019; Masuzawa et al., 2013; McCully et al., 2009) and patients (Guariento et al., 2021; Emani et al., 2017) acutely improves ventricular function and reduces heart injury. Despite these therapeutical benefits, isolation of mitochondria is a technically challenging and labor- intensive process (Bensley & Hoerr, 1934; Sims, 1990; Hubbard et al., 2019; McCully et al., 2017), mitochondria activity rapidly diminishes after isolation (McCully et al., 2017), and
[0004] 34865-9395-0642, v. 1 bioenergetic enhancement of delivered mitochondria is short-lived (Ali Pour et al., 2020). Therefore, the isolation and delivery of mitochondria is difficult to scale clinically and thus, there is an unmet need for innovative strategies that can effectively improve mitochondrial function and energy production in the heart without laborious isolation procedures. Human cells, including cardiomyocytes (CMs), rely upon a variety of nuclear encoded genes that act across synergistic pathways to orchestrate the generation of new mitochondria. Often regarded as the master regulator of mitochondrial biogenesis, PPARGC1A (also known as 3*&^Į) is a key transcription factor that coordinates expression of genes needed for mitochondrial biogenesis (Wu et al., 1999; Puigserver et al., 1998; Lin et al., 2005; Finck & Kelly, 2006). However, this critical process is also regulated by additional genes such as PPARGC1B (also known as 3*&^ȕ), NRF2, and TFAM, among many others (Scarpulla, 2011; Scarpulla, 2008; Villena, 2015). While many of these genes have posttranslational modifications (PTMs) that control their activity, increased levels of their corresponding RNA expression nevertheless lead to an increase in cellular mitochondria (Wu et al., 1999; Puigserver et al., 1998; St-Pierre et al., 2003; van Tienen et al., 2010). In fact, the forced overexpression of these genes can lead to an increase in mitochondria quantity (Wu et al., 1999; Puigserver et al., 1998; St-Pierre et al., 2003; van Tienen et al., 2010) and / or function (Baar et al., 2003; Ikeuchi et al., 2005; Maniura-Weber et al., 2004; Piantadosi et al., 2008; Khan et al., 2018). In particular, cDNA overexpression of PPARGC1A has been observed to increase mitochondria quantity and function protecting against cardiac dysfunction (Shi et al., 2013). However, the overexpression of these genes must be carefully controlled, as overexpression leads to pathological states. Thus, interventions to precisely modulate the expression of nuclear genes orchestrating mitochondrial biogenesis have the potential to restore energetic balance, enhance cardiac function, and ultimately mitigate cardiac disease progression. Current techniques to enhance mitochondrial biogenesis rely upon overexpression of single cDNAs encoding single gene isoforms. However, this methodology fails to capture the functional diversity of alternative genetic isoforms (Uhlén et al., 2015; Wang et al., 2008) and cannot recapitulate the synergistic interactions among genes / cellular pathways (Mitschka & Mayr, 2022; Solovieff et al., 2013; Tyson et al., 2001). As such, improved approaches that solve the challenges plaguing current methodologies are urgently needed.
[0005] 44865-9395-0642, v. 1 SUMMARY Thus, in accordance with the present disclosure, there is provided a method of increasing mitochondria in a cell or increasing mitochondrial activity in a cell comprising introducing into said cell fusion protein comprising a DNA-binding protein (DBP) construct fused to a transcriptional regulator that modulates endogenous mitochrondrial gene expression. The fusion protein may modulate expression of one or more of PPARGC1A, PPARGC1B, NFE2L2, NRF1, TFAM genes, TFB2M, NRF2, SRIT1, GSK3B, or KEAP1. The DBP may be a Cas9, such as Staphylococcus aureus dCa9 (SadCas9), or a zinc finger DBP, or a TALE. The DBP is a Cas9, such as dCas9, such as Staphylococcus aureus dCa9 (SadCas9), and the transcriptional regulator may be a transactivator, such as VP64, or a transcriptional repressor, such as a KRAB domain or DNA methyl transferase domain. The SadCa9 fusion to VP64 may be further fused to eNRF2-MRTF-A-STAT1 (NMS) transcriptional activation domains, such as wherein the 5’ to 3’ configuration of elements is NMS-SadCa9-VP64. PPARGC1A and NRF1 genes, PPARGC1A and TFAM genes, NRF1 and TFAM genes, PPARGC1A and PPARGC1B genes, PPARGC1B and NRF1 genes, PPARGC1B and TFAM genes, PPARGC1A, NRF1 and TFAM genes, PPARGC1A, PPARGC1B, and TFAM genes, PPARGC1A, PPARGC1B, and NRF1 genes or PPARGC1A, PPARGC1B, NRF1 and TFAM genes may be targeted and activated. The DBP may bea Cas9 and a gRNA targeting sequence is included, such as selected from: CRISPR Target gRNA Sequence SadCas9 PPARGC1A 1 ATGCTGTGATTAAAGCCAGCTTTGAAT (SEQ ID NO: 1) SadCas9 PPARGC1A 2 CACTGAAGCAGAGGGCTGCCTTTGAGT (SEQ ID NO: 2) SadCas9 PPARGC1A 3 GGGCTGCCTTTGAGTGACGTCACGAGT (SEQ ID NO: 3) SadCas9 PPARGC1A 4 GCACAGGGGAAGGGAGGCTGGGTGAGT (SEQ ID NO: 4) AsdCas12a PPARGC1A 1 TTTAAAGCGTTACTTCACTGAAGCAGA (SEQ ID NO: 5) AsdCas12a PPARGC1A 2 TTTGAGTGACGTCACGAGTTAGAGCAG (SEQ ID NO: 6)
[0006] 54865-9395-0642, v. 1 AsdCas12a PPARGC1A 3 TTTAATAGCTTTGTCATGTGACTGGGG (SEQ ID NO: 7) AsdCas12a PPARGC1A TTTGTCATGTGACTGGGGACTGTAGTA (SEQ ID NO: 8) EnAsdCas12a PPARGC1A TGTAGTAAGACAGGTGCCTTCAGTTCA (SEQ ID NO: 9) SadCas9 PPARGC1B CAGCTCACGCAGCCCTCAGCAAGGGGT (SEQ ID NO: 10) SadCas9 PPARGC1B CGCCAGACACGGCGCAGGAAAGTGGGT (SEQ ID NO: 11) SadCas9 PPARGC1B CGCGCGGCGCCCGCGGGAGCCGGGGGT (SEQ ID NO: 12) SadCas9 PPARGC1B CGAGCAAGGGAGGAGGGAGGAGGGAGT (SEQ ID NO: 13) SadCas9 TFAM GCCAGAGCCCTCCGCAGGCTAGAGGAT (SEQ ID NO: 14) SadCas9 TFAM CGGTGGGCGGCCTTGCGGGGGAGGAAT (SEQ ID NO: 15) SadCas9 TFAM CTCCCCCGCAAGGCCGCCCACCGGGGT (SEQ ID NO: 16) SadCas9 TFAM CGCCCCGCCCCCATCTACCGACCGGAT (SEQ ID NO: 17) SadCas9 NRF1 GGGCCGGAACCTCAAAAGCAACTGGAT (SEQ ID NO: 18) SadCas9 NRF1 TCCGTGCACGCGACGCGGCGGCGGGGT (SEQ ID NO: 19) AsdCas12a NRF1 TTTGGAGGGGGCCGGAACCTCAAAAGC (SEQ ID NO: 20 AsdCas12a NRF1 TTTGAGGTTCCGGCCCCCTCCAAACCT (SEQ ID NO: 21) EnAsdCas12a NRF1 TGTGCTGCGGGCAGGCAGCGGAGAGGG (SEQ ID NO: 22) EnAsdCas12a NRF1 CTTCCCCGCCCGGCCGCCGCCATGATG (SEQ ID NO: 23). The DBP construct may be delivered to said cell in an integrative vector or non- integrating vector, such as an adeno-associated viral vector or a non-integrating lentiviral
[0007] 64865-9395-0642, v. 1 vector. The DBP construct may be delivered to said cell in a non-viral vector, such as a lipid nanoparticle, by electroporation, or by microinjection. The cell may be an isolated cell treated ex vivo and subsequently administered to a living subject. The cell may be located in a living subject. The living subject may suffer from a disease or disorder characterized by mitochondrial dysfunction, such as wherein the disease or disorder is cardiovascular disease, a respiratory disease, a musculoskeletal disease, a reproductive disease, a digestive disease, or a neuromuscular disease. The subject may suffer from a disease, disorder or injury for which improved mitochondrial function would be therapeutic, or wherein the subject does not suffer from a disease, disorder or injury for which improved mitochondrial function would be therapeutic and is treated to improve normal bioenergetics, such as wherein the disease, disorder or injury is a wound. Also provided is a nucleic acid construct encoding a fusion protein comprising a DNA- binding protein (DBP) construct fused to a transcriptional regulator. The DBP may be a Cas9, such as dCas9, such as Staphylococcus aureus dCa9 (SadCas9), or a zinc finger DBP, or a TALE. The construct may comprise, in a 5’ to 3’ order, coding sequences for (a) eNRF2- MRTF-A-STAT1 (NMS) transcriptional activation domains, (b) SadCas9, and (c) VP64. The nucleic acid construct may be an integrative vector or non-integrating vector, such as an adeno- associated viral vector or a non-integrating lentiviral vector. The DBP construct may be disposed in a non-viral vector, such as a lipid nanoparticle, by electroporation, or by microinjection. Further provided is a fusion protein comprising a DNA-binding protein (DBP) construct fused to a transcriptional regulator that modulates endogenous mitochondrial gene expression. The fusion protein may modulate expression of one or more of PPARGC1A, PPARGC1B, NFE2L2, NRF1, TFAM genes, TFB2M, NRF2, SRIT1, GSK3B, or KEAP1. The DBP may be a Cas9, such as dCas9, Staphylococcus aureus dCa9 (SadCas9), or a zinc finger DBP, or a TALE. The DBP may be a Cas9, such as dCas9, such as Staphylococcus aureus dCa9 (SadCas9), wherein the transcriptional regulator may be a transactivator, such as VP64, or a transcriptional repressor, such as a KRAB domain or DNA methyl transferase domain. The SadCa9 fusion to VP64 may be further fused to eNRF2-MRTF-A-STAT1 (NMS) transcriptional activation domains, such as wherein the 5’ to 3’ configuration of elements is NMS-SadCa9-VP64. Additionally, there is provided a kit comprising nucleic acid construct as described here. The kit DBP may be a Cas9, such as dCas9 or SadCas9 and the kit may further comprise one
[0008] 74865-9395-0642, v. 1 or more guide RNA (gRNA) that targets dCas9 or SadCas 9 to one or more of PPARGC1A, PPARGC1B, NFE2L2, NRF1 and TFAM genes, TFB2M, NRF2, SRIT1, GSK3B, or KEAP1,and even further optionally including receptacles to contain the nucleic acid construct, gRNAs, packaging to hold said receptacles, and / or instructions for use. The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and / or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” The word “about” means plus or minus 5% of the stated number. It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein. Other objects, features and advantages of the present disclosure will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the disclosure, are given by way of illustration only, since various changes and modifications within the spirit and scope of the disclosure will become apparent to those skilled in the art from this detailed description.
[0009] 84865-9395-0642, v. 1 BRIEF DESCRIPTION OF THE DRAWINGS The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure. The disclosure may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein. FIGS. 1A-B. (FIG. 1A) CRISPR activation (CRISPRa) tools such as Staphylococcus aureus dead Cas9 (SadCas9) fused to NMS and VP64 (Mahata et al., 2022) or the VPR tripartite domain (Chavez et al., 2015) are schematically depicted along with nuclear localization signals (NLS) and FLAG epitopes. (FIG. 1B) CRISPRa enables targeted activation of endogenous transcript isoforms that have advantages over conventional cDNA overexpression. Figure adapted from Escobar and Li et al. 2022 (Escobar et al., 2022). FIGS. 2A-D. (FIG. 2A) Comparison of NMS (NMS-SadCas9-VP64) and canonical VPR (SadCas9-VPR) in HEK293T cells. (FIGS.2B-C) Total (FIG.2B) and endogenous (FIG. 2C) expression of PPARGC1A transcript produced by CRISPRa (NMS) and cDNA overexpression, respectively, in HEK293T cells. (FIG.2D) Relative endogenous expression of PPARGC1A in different human cells HFF (CCD1112-Sk), HDF (HDFa), human cardiomyocytes (CMs; AC16) and rat myoblast (RM; L6). FIGS. 3A-B. Copies of mitochondrial DNA (mtDNA) (FIG. 3A) and representative fluorescence microscopy of stained mitochondria (TMRE; FIG. 3B) following CRISPRa targeting or cDNA overexpression of PPARGC1A DFURVV^LQGLFDWHG^FHOO^W\SHV^^6FDOH^EDU^ ^^^^P^ FIGS. 4A-C. (FIG. 4A) Normalized oxygen consumption rate (OCR) following delivery of CRISPRa targeting of cDNA overexpression of PPARGC1A in human CMs (AC16) measured with Seahorse XFe96. (FIGS.4B-C) Cellular ATP production (FIG.4B) and maximal respiration (FIG. 4C) based on results in FIG. 4A. FIGS. 5A-B. (FIG. 5A) The inventors can achieve activation of 12 different endogenous human loci using CRISPRa (adapted from Mahata et al., 2022). (FIG. 5B) Copies of mtDNA following delivery of CRISPRa targeting of PPARGC1A (1A) or PPARGC1B (1B) individually or in combination (multiplex) in HEK293T cells. Results obtained using cDNA overexpression of these molecules are also shown.
[0010] 94865-9395-0642, v. 1 FIGS. 6A-C. The inventors have used high-throughput CRISPRa screening to identify novel drivers of chemotherapeutic resistance in human melanoma cells. (FIG. 6A) Overview of CRISPRa screening strategy. (FIG. 6B) Distribution of gRNA frequencies after lentiviral transduction in DMSO or PLX-4720 treated A375 cells. (FIG.6C) gRNA counts in PLX-4720 versus DMSO treated A375 cells. Blue circles indicate depleted gRNAs, red circles indicate enriched gRNAs, and gray circles indicate gRNAs with no change. Adapted from Li et al., 2021 (Li et al., 2021). FIG. 7. Schematic depiction of high-throughput CRISPRa library-based identification of novel drivers of mitochondria biogenesis. FIGS.8A-C. Representative microscopy (FIG.8A), wound area (FIG.8B), and wound closure rate (FIG.8C) of cell migration over a 35-hour period following CRISPRa targeting or cDNA overexpression of PPARGC1A in MSCs. FIG 9. CRISPRa increases mitochondria in vivo. CRISPRa was transduced into rat hindlegs, and 7 days post-injection, hindleg muscle from Sprague Dawley animals was harvested. Tissue samples were immunoassayed against a mitochondrial marker (TOMM20), and the degree of staining was quantified. Vehicle = WT; CRISPRa = 4 x 107TU / animal. Samples FIG. 10. CRISPRa and cDNA increase isolated mitochondria. Human HEK293T cells were transfected with CRISPRa or cDNA for PPARGC1A using qPCR. 3 days after transfection (using calcium phosphate with 10 cm dish), mitochondria was extracted from cells and quantified along with wild-type cells and cytoplasmic extractions.
[0011] 104865-9395-0642, v. 1 DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS This present disclosure provides compositions and methods to endogenously increase the levels of mitochondria of any human cell. The described tool has been designed with cross- platform compatibility in mind. This system results in a noticeable increase (double the control) of mitochondria in the cells targeted cells. Conventional cDNA isoforms are used in the field for their effectiveness in the target cells, but these cDNAs are not as potent in other cellular contexts due to different tissue / organs having a preference for particular cDNA isoforms. Using the materials and method described herein, the inventors propose a more universal solution to increase mitochondria in cells, rather than having to optimize different cDNA isoform combinations for a particular condition, thus producing a significant advance in this field. Using the Staphylococcus aureus dCas9 (SadCas9), the inventors have selected a dCas protein variant that is smaller than the traditional Streptococcus pyogenes dCas9 (SpdCas9). This change is important for the use of the tool in viral systems with smaller packaging ability, like adeno-associated viruses (AAV). Yet by selecting the SadCas9 over smaller dCas proteins, like dCas12j2 or dCas12j3, they maintain the selectivity and effectiveness of the tool in comparison to other dCas variants (Escobar et al., 2022). Similarly, they selected NMS-dCas- VP64, as the transactivator module, due to the system generating the highest level of gene activation in human cells in comparison to conventional transactivation modules (i.e., dCas- VPR). Additionally, the NMS-dCas-VP64 module is derived from more human proteins than conventional modules, which will ameliorate potential issues regarding immune reaction from patients receiving the tool in vivo. The key targets of have also been identified by selecting targets that result in the highest level of gene transcription, in order to account for potential dosage effects from differing tool delivery efficiency. Additionally, the ability to increase mitochondrial levels in the cell would be valuable in the treatment of many diseases or conditions, including but not limited to, heart attacks, wound healing, skin aging (Singh et al., 2018), or hair loss (Singh et al., 2018), as the increase of mitochondria produces beneficial effects in the tested conditions. Currently, mitochondria treatments focus on the delivery of cDNA overexpression constructs, which lack the isoform diversity the cell naturally produces, or the delivery of isolated autologous mitochondria, which have a limited lifespan and require technical expertise to produce. These compositions and methods act as an off-the-shelf solution for diseases or conditions requiring increased mitochondria. These and other aspects of the disclosure are described in detail below.
[0012] 114865-9395-0642, v. 1 I. Mitochondrial Biogenesis Mitochondrial biogenesis is the process by which cells increase mitochondrial numbers. It was first described in the 1960s, when it was discovered that physical endurance training induced higher mitochondrial content levels, leading to greater glucose uptake by muscles. Mitochondrial biogenesis is activated by numerous different signals during times of cellular stress or in response to environmental stimuli, such as aerobic exercise. The ability for a mitochondrion to self-replicate is rooted in its evolutionary history. It is commonly thought that mitochondria descend from cells that formed endosymbiotic relationships with Į-protobacteria; they have their own genome for replication. However, recent evidence suggests that mitochondria may have evolved without symbiosis. The mitochondrion is a key regulator of the metabolic activity of the cell and is also an important organelle in both production and degradation of free radicals. It is postulated that higher mitochondrial copy number (or higher mitochondrial mass) is protective for the cell. Mitochondria are produced from the transcription and translation of genes both in the nuclear genome and in the mitochondrial genome. The majority of mitochondrial protein comes from the nuclear genome, while the mitochondrial genome encodes parts of the electron transport chain along with mitochondrial rRNA and tRNA. Mitochondrial biogenesis increases metabolic enzymes for glycolysis, oxidative phosphorylation and ultimately a greater mitochondrial metabolic capacity. However, depending on the energy substrates available and the redox state of the cell, the cell may increase or decrease the number and size of mitochondria. Critically, mitochondrial numbers and morphology vary according to cell type and context-specific demand, whereby the balance between mitochondrial fusion / fission regulates mitochondrial distribution, morphology, and function. Since the majority of mitochondrial protein comes from the nuclear genome, the proteins need to be properly targeted and transported into the mitochondria to perform their functions. First, mRNA is translated in the cell’s cytosol. The resulting unfolded precursor proteins will then be able to reach their respective mitochondrial compartments. Precursor proteins will be transported to one of four areas of the mitochondria, which include the outer membrane, inner membrane, intermembrane space, and matrix. All proteins will enter the mitochondria by a translocase on the outer mitochondrial membrane (TOM). Some proteins will have an N-terminal targeting signal, and these proteins will be detected and transported into the matrix, where they will then be cleaved and folded. Other proteins may have targeting information in their sequences and will not include an N-terminal signal. During the past two
[0013] 124865-9395-0642, v. 1 decades, researchers have discovered over thirty proteins that participate in mitochondrial protein import. As researchers learn more about these proteins and how they reach the respective mitochondrial compartments that utilize them, it becomes evident that there is a multitude of processes that work together in the cell to allow for mitochondrial biogenesis. Mitochondria are highly versatile and are able to change their shape through fission and fusion events. Definitively, fission is the event of a single entity breaking apart, whereas fusion is the event of two or more entities joining to form a whole. The processes of fission and fusion oppose each other and allow the mitochondrial network to constantly remodel itself. If a stimulus induces a change in the balance of fission and fusion in a cell, it could significantly alter the mitochondrial network. For example, an increase in mitochondrial fission would create many fragmented mitochondria, which has been shown to be useful for eliminating damaged mitochondria and for creating smaller mitochondria for efficient transporting to energy-demanding areas. Therefore, achieving a balance between these mechanisms allows a cell to have the proper organization of its mitochondrial network during biogenesis and may have an important role in muscle adaptation to physiological stress. In mammals, mitochondrial fusion and fission are both controlled by GTPases of the dynamin family. The process of mitochondrial fission is directed by Drp1, a member of the cytosolic dynamin family. This protein forms a spiral around mitochondria and constricts to break apart both the outer and inner membranes of the organelle. On the other hand, the process of fusion is directed by different membrane-anchored dynamin proteins at different levels of the mitochondria. Fusion at the level of the outer mitochondrial membrane is mediated by Mfn1 and Mfn2 (Mitofusins 1 and 2), and fusion at the level of the inner mitochondrial membrane is mediated by Opa1. Multiple research studies have observed correlated increases between mitochondrial respiratory capacity with Mfn1, Mnf2, and Drp1 gene expression after endurance exercises. Therefore, it is supported that reorganization of the mitochondrial network in muscle cells plays an important role in response to exercise. PGC-^Į^^D^PHPEHU^RI^ WKH^SHUR[LVRPH^SUROLIHUDWRU-activated receptor gamma (PGC) family of transcriptional coactivators, is the master regulator of mitochondrial biogenesis. It is known to co-activate nuclear respiratory factor 2 (NRF2 / GABPA), and together with NRF-2 coactivates nuclear respiratory factor 1 (NRF1). The NRFs, in turn, activate the mitochondrial transcription factor A (tfam), which is directly responsible for transcribing nuclear-encoded mitochondrial proteins. This includes both structural mitochondrial proteins as well as those involved in mtDNA transcription, translation, and repair. PGC- ^ȕ^^D^SURWHLQ^WKDW^LV^VWUXFWXUDOO\^
[0014] 134865-9395-0642, v. 1 similar to PGC-^Į^^LV^DOVR^LQYROYHG^LQ^UHJXODWLQJ^PLWRFKRQGULDO^ELRJHQHVLV^^EXW^GLIIHUV^LQ^WKDW^ it does not get increased in response to exercise. While there have been significant increases in mitochondria found in tissues where PGC-^Į^LV^RYHUH[SUHVVHG^^DV^WKH^FRIDFWRU^LQWHUDFWV^ZLWK^ these key transcription factors, knockout mice with disrupted PGC-^Į^DUH^VWLOO^YLDEOH^DQG^VKRZ^ normal mitochondrial abundance. Thus, PGC-^Į^ LV^QRW^ UHTXLUHG^ IRU^QRUPDO^GHYHORSPHQW^RI^ mitochondria in mice, but when put under physiological stress, these mice exhibit diminished tolerance compared to mice with normal levels of PGC-^Į^ Similarly, in knockout mice with disrupted PGC-^ȕ^^ WKH^ PLFH^ VKRZHG^ PRVWO\^ QRUPDO^ OHYHOV^ RI^ PLWRFKRQGULDO^ IXQFWLRQ^ ZLWK^ decreased ability to adapt to physiological stress. However, a double knockout experiment of PGC-^Į^ȕ^ FUHDWHG^ PLFH^ WKDW^ GLHG^ PRVWO\^ ZLWKLQ^ ^^^ KRXUV^ E\^ GHIHFWV^ LQ^ PLWRFKRQGULDO^ maturation of cardiac tissue. These findings suggest that while both PGC-^Į^DQG^3*&- ^ȕ^GR^ not each solely establish a cell’s ability to perform mitochondrial biogenesis, together they are able to complement each other for optimal mitochondrial maturation and function during periods of physiological stress. AMP-activated kinase (AMPK) also regulates mitochondrial biogenesis by phosphorylating and activating PGC-^Į^XSRQ^VHQVLQJ^DQ^HQHUJ\^GHILFLHQF\^LQ^PXVFOH^ In mice with reduced ATP / AMP ratios that would occur during exercise, the energy depletion has been shown to correlate with AMPK activation. AMPK activation then continued to activate PGC- ^Į^DQG^15)V^LQ^WKHVH^PLFH^^DQG^PLWRFKRQGULDO^ELRJHQHVLV^ZDV^VWLPXODWHG^ The capacity for mitochondrial biogenesis has been shown to decrease with age, and such decreased mitochondrial function has been associated with diabetes and cardiovascular disease. Aging and disease can induce changes in the expression levels of proteins involved in the fission and fusion mechanisms of mitochondria, thus creating dysfunctional mitochondria. One hypothesis for the detrimental results of aging is associated with the loss of telomeres, the end segments of chromosomes that protect genetic information from degradation. Telomere loss has also been associated with decreased mitochondrial function. Deficiency of telomerase reverse transcriptase (TERT), an enzyme that plays a role in preserving telomeres, has been correlated with activated p53, a protein that suppresses PGC- ^Į^ Therefore, the loss of telomeres and TERT that comes with aging has been associated with impaired mitochondrial biogenesis. AMPK expression has also been shown to diminish with age, which may also contribute to suppressing mitochondrial biogenesis.
[0015] 144865-9395-0642, v. 1 II. CRISPR-Based Systems Employing Transcriptional Activation Domains / Activators A. TADs The inventors previously explored the transcription activation properties of a variety transcriptional activation domains (TAD) from human transcription factors. See PCT / US23 / 61620. They selected the previously identified potent activator combination of NMS and VP64, the former composed of the two fused TAD domains of NRF2 namely Neh4 and Neh5 (designated eNRF2), the TAD domain of MRTF-A, and the TAD domain of STAT1. Additionally, they selected the state-of-the-art transcriptional activator VPR (VP64-p65- Rta) as a comparative benchmark. They used three biomedically relevant CRISPR / dCas systems, Staphylococcus aureus dCas9 (SadCas9), Acidaminococcus sp. dCas12a (AsdCas12a), and an engineered Acidaminococcus sp. dCas12a (EnAsdCas12a) to specifically deliver their TADs. Thus, they constructed different combinations of TADs (NMS-VP64 or VPR) with dCas systems (SadCas9, AsdCas12a, EnAsdCas12a) in lentivirus-compatible isogenic plasmid backbones. They tested the transcriptional activation ability of each CRISPR activation system (CRISRPa; combination of dCas with TAD) targeting upstream of the PPARGC1A (PGC-^Į) transcription start site (TSS). Interestingly, the inventors observed that the NMS-SadCas9- VP64 CRISPRa system resulted in higher and more consistent activation of PPARGC1A. They determined the optimal activation targeting location of the NMS-SadCas9-VP64 for the PPARGC1A (PGC-^ȕ), NRF1, and TFAM, which informed future targeted for endogenous activation of mitochondrial biogenesis. B. Cas Proteins Cas (CRISPR associated protein) molecules play a vital role in the immunological defense of certain bacteria against DNA viruses and plasmids and is heavily utilized in genetic engineering applications. Its main function is to cut DNA and thereby alter a cell’s genome. Cas9 is perhaps the most studied of all the Cas molecules. It is a dual RNA-guided DNA endonuclease enzyme associated with the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) adaptive immune system in Streptococcus pyogenes. S. pyogenes utilizes CRISPR to memorize and Cas9 to later interrogate and cleave foreign DNA, such as invading bacteriophage DNA or plasmid DNA. Cas9 performs this interrogation by unwinding foreign DNA and checking for sites complementary to the 20 bP spacer region of the guide RNA. If the DNA substrate is complementary to the guide RNA, Cas9 cleaves the
[0016] 154865-9395-0642, v. 1 invading DNA. In this sense, the CRISPR-Cas9 mechanism has a number of parallels with the RNA interference (RNAi) mechanism in eukaryotes. Apart from its original function in bacterial immunity, the Cas9 protein has been heavily utilized as a genome engineering tool to induce site-directed double-strand breaks in DNA. These breaks can lead to gene inactivation or the introduction of heterologous genes through non-homologous end joining and homologous recombination respectively in many laboratory model organisms. Alongside zinc finger nucleases and Transcription activator-like effector nuclease (TALEN) proteins, Cas9 is becoming a prominent tool in the field of genome editing. Cas9 has gained traction in recent years because it can cleave nearly any sequence complementary to the guide RNA. Because the target specificity of Cas9 stems from the guide RNA:DNA complementarity and not modifications to the protein itself (like TALENs and zinc fingers), engineering Cas9 to target new DNA is straightforward. Versions of Cas9 that bind but do not cleave cognate DNA can be used to locate transcriptional activator or repressors to specific DNA sequences in order to control transcriptional activation and repression. Native Cas9 requires a guide RNA composed of two disparate RNAs that associate – the CRISPR RNA (crRNA), and the trans-activating crRNA (tracrRNA). Cas9 targeting has been simplified through the engineering of a chimeric single guide RNA (chiRNA). Other useful Cas proteins include Cas6, AsdCas12a, SpdCas9, CjdCas9, and SadCas9. C. VP64 VP64 is a transcriptional activator composed of four tandem copies of VP16 (Herpes Simplex Viral Protein 16, amino acids 437-447*: DALDDFDLDML) connected with glycine- serine (GS) linkers. When fused to another protein domain that can bind near the promoter of a gene, VP64 acts as a strong transcriptional activator. This module is a classic molecular biology tool. *Note: numbering excludes the starting methionine so the first amino acid is actually 438, consistent with the Uniprot entry UL48. D. Linkers Linkers are short peptide segments that permit the “fusion” of two often larger peptide or polypeptide regions such that the functionalities of the larger regions are not impaired or physically constrained by direct linkage at their termini. Linkers are often characterized by polar uncharged or charged residues, flexibility (although some applications benefit from rigid linkers) and secondary structures of particular nature.
[0017] 164865-9395-0642, v. 1 Flexible GS linkers contain, not surprisingly, glycine and serine residues, including GGS, GSSGSS (SEQ ID NO: 24), and GSSSSSS (SEQ ID NO: 25). A particular example is (GGGGS)3 (SEQ ID NO: 26). Another linker, called XTEN, is a short (16 aa) flexible peptide segment with no specific structure. E. gRNA A small guide RNA (sgRNA), or gRNA is an RNA with around 20 nucleotides used to direct Cas9 or dCas9 to their targets. gRNAs contain two major regions of importance for CRISPR systems: the scaffold and spacer regions. The spacer region has nucleotides that are complementary to those found on the target genes, often in the promoter region. The scaffold region is responsible for formation of a complex with (d)Cas9. Together, they bind (d)Cas9 and direct it to the gene(s) of interest. Since the spacer region of a gRNA can be modified for any potential sequence, they give CRISPR systems much more flexibility as any genes and nucleotides with a sequence complementary to the spacer region can become possible targets. F. Delivery Systems Delivery systems for the CRISPR-based systems of the present disclosure include integrative vectors such as retroviral or lentiviral system, or transient delivery systems, such as adeno-associated virus (AAV) or non-integrating lentiviruses. In embodiments, the AAV vector is replication-defective or conditionally replication defective. In embodiments, the AAV vector is a recombinant AAV vector. In some embodiments, the AAV vector comprises a sequence isolated or derived from an AAV vector of serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11 or any combination thereof. Delivery systems also include non-viral methods such as lipid nanoparticles and / or mRNA delivery. III. Formulation and Administration The present disclosure provides pharmaceutical compositions. Such compositions comprise a prophylactically or therapeutically effective amount of an agent, and a pharmaceutically acceptable carrier. In a specific embodiment, the term “pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term “carrier” refers to a diluent, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such
[0018] 174865-9395-0642, v. 1 as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a particular carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Other suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. Oral formulations can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical agents are described in “Remington's Pharmaceutical Sciences.” Such compositions will contain a prophylactically or therapeutically effective amount of the agent, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration, which can be oral, intravenous, intraarterial, intrabuccal, intranasal, nebulized, bronchial inhalation, intra-rectal, vaginal, topical or delivered by mechanical ventilation. Pharmaceutically acceptable salts include the acid salts and those which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like. Generally, the ingredients of compositions of the disclosure are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water-free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
[0019] 184865-9395-0642, v. 1 IV. Applications The ability to increase mitochondrial levels in a cell would be valuable in the treatment of many diseases or conditions, including but not limited to, diabetes, cancers or pre-cancers, cardiovascular disease including cardiomyopathies and myocardial infarction / ischemia, wound healing, muscle repair, skin aging, neuropathies (neurodegenerative disease, stroke, demyelinating disease, ataxia, epilepsy, Parkinsonism, migraines, cognitive decline, psychological symptoms), liver disease, visual impairment (retinitis pigementosa, optic neuropathy, cataracts), hearing deficits, diabetes, malabsorption, kidney dysfunction, reproductive diseases (infertility, premature menopause), anemia, lactacidemia, immune deficiency, and hair loss. General categories of defects include defects in mtDNA maintenance and translation, mt protein synthesis, and mtDNA expression. Specific defects include those in ATP synthase, oxidative phosphorylation, reducing equivalents, electrochemical potential, and lactic acidosis. An extensive list of diseases and disorders can be found, along with responsible genes, in Suomalainen & Battersby (2018) which is specifically incorporated herein by reference. V. Examples The following examples are included to demonstrate preferred embodiments. It should be appreciated by those of skill in the art that the techniques disclosed in the examples that follow represent techniques discovered by the inventor to function well in the practice of embodiments, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the disclosure. Example 1 Deactivated CRISPR systems are powerful tools to manipulate gene expression. Conventional CRISPR-based genome editing (i.e., cutting / permanently altering genomic DNA) is poised to expand new gene therapies for precise editing of genetic conditions (Madigan et al., 2023; Li et al., 2023; Khoshandam et al., 2023). However, in parallel to the development of CRISPR / Cas9-based tools for conventional genome editing, the inventors and others have developed nuclease-null / dead “dCas9”-based technologies that have emerged as powerful tools to engineer endogenous human gene expression (FIGS. 1A-B) (Hilton et al., 2015; Kabadi et
[0020] 194865-9395-0642, v. 1 al., 2014; Thakore et al., 2016; Klann et al., 2017; Hilton & Gersbach, 2015; Escobar et al., 2022; Gemberling et al., 2021; Goell & Hilton, 2021; Lee et al., 2020; Li et al., 2021; Wang et al., 2022; Zhao et al., 2023; Mahata et al., 2022; Guerra-Resendez & Hilton, 2022). As with traditional CRISPR technologies, the targeting of these nuclease-null dCas systems to a specific genomic site is controlled using engineered guide RNAs (gRNAs), which provides opportunities to tailor the epigenome and gene expression at specific genomic loci. dCas9 is leveraged in these contexts as a programmable DNA binding platform that in turn can recruit epigenetic and / or transcriptional modifiers (most commonly via direct protein fusion or aptamer- or antibody-based recruitment) to genomic loci in human / mammalian cells without any cutting (Mahata et al., 2022). Recently, the inventors developed hypercompact CRISPR / Cas-based transcriptional activation (CRISPRa) modules that are hyper specific, compact, and have reduced cytotoxicity in clinical-grade human cells and primary mouse neurons (In Press, Nature Methods)(Mahata et al., 2022). Using the smaller yet effective Staphylococcus aureus dCas9 (hereafter dCas9), the inventors’ recently developed hypercompact CRISPRa system enables both potent transcriptional activation and smaller payload delivery. Here, the inventors have used these new tools to activate endogenous mitochondrial biogenesis genes and in turn improve mitochondrial numbers and functions in murine and human cells (FIGS. 2A-5B) (Mahata et al., 2022; Chavez et al., 2015). Multiplexed CRISPRa for mitochondrial biogenesis. Cellular processes do not occur in isolation, which results in crosstalk among pathways that, in turn, can synergize and augment cellular processes (Mitschka & Mayr, 2022; Solovieff et al., 2013; Tyson et al., 2001). In the case of mitochondrial biogenesis, there are numerous independent pathways that directly affect the creation of new mitochondria (Scarpulla et al., 2011; Jornayvaz & Shulman, 2010; Ploumi et al., 2017; Dominy & Puigserve, 2013), such as pathways controlling the availability of phospholipids (Heden et al., 2016; Gohil & Greenberg, 2009) or amino acid abundance (Ragni et al., 2023; Nisoli et al., 2008; Valerio et al., 2011). Similarly, there are several other independent pathways that have been observed to indirectly alter mitochondria biogenesis (Kelly & Scarpulla, 2004; Lefterova & Lazar, 2009; Sun et al., 2016; Gureev et al., 2019; Nisoli et al., 2005; Lanza et al., 2012; Lowell & Spiegelman, 2000; Garcia-Roves et al., 2007), such as adipogenesis (Kelly & Scarpulla, 2004; Lefterova & Lazar, 2009) or even cellular aging (Sun et al., 2016; Gureev et al., 2019). Activation of multiple factors can be key for efficient biological control (Balboa et al., 2015; Garbern & Lee, 2021), thus pathways that are independent yet convergently associated with mitochondrial function are unique targets for
[0021] 204865-9395-0642, v. 1 enhancing mitochondria biogenesis. The inventors and others have pioneered the use of CRISPRa systems to activate multiple genes simultaneously or “multiplex” engineered gene activation inside a single cell (Hilton et al., 2015; Kabadi et al., 2014; Escobar et al., 2022; Li et al., 2021; Black et al., 2016; Mahata et al., 2022; Chavez et al., 2015; Qi et al., 2013; Gilbert et al., 2013), and they have indeed observed increased mitochondrial biogenesis when targeting multiple genes simultaneously in human cells (FIG. 5B). Therefore, CRISPRa-based multiplexed gene activation is uniquely positioned to harness the intrinsic biological synergy associated with mitochondrial biogenesis to both access new therapeutic opportunities in MI and HF, and to improve the fundamental understanding of the biological pathways supporting endogenous mitochondrial synthesis and function. CRISPRa targeting of endogenous genes robustly increases gene expression in diverse cells including human cardiomyocytes. The inventors have extensive experience harnessing CRISPRa technologies to modulate gene expression in cells (Hilton et al., 2015; Kabadi et al., 2014; Klann et al., 2017; Escobar et al., 2022; Gemberling et al., 2021; Lee et al., 2020; Li et al., 2021; Wang et al., 2022; Mahata et al., 2022), to interrogate genomic regulatory mechanisms (Hilton et al., 2015; Wang et al., 2022), and to control complex biological processes (Li et al., 2021; Mahata et al., 2022). They will use CRISPRa to induce mitochondria biogenesis through targeted activation of endogenous genes within the pathway. The inventors have validated the established SadCas9-VPR (dCas9-VPR) CRISPRa system (Wang et al., 2022; Chavez et al., 2015), which consists of viral transcriptional activation domains, in human HEK293T cells to robustly activate PPARGC1A expression (FIG. 2A). However, the inventors have shown that dCas9-VPR can display cytotoxicity in primary human cell types (Mahata et al., 2022), which is a major concern in slowly replicating / primary cells, such as cardiomyocytes (Soonpaa & Field, 1998; Kajstura et al., 1998). To address this, the inventors recently developed new CRISPRa systems that are more potent, smaller, better expressed, and less toxic than conventional CRISPRa systems (Mahata et al., 2022), including dCas9-VPR. The inventors’ experiments with one of these systems (called NMS-SadCas9- VP64), enabled them to robustly activate endogenous PPARGC1A expression in human HEK293T cells (FIG. 2A). The inventors also compared the transcript levels produced by NMS-SadCas9-VP64, referred to herein as CRISPRa, system to a cDNA PPARGC1A overexpression system and found that the total amount of PPARGC1A transcripts resulting from the cDNA system was substantially higher than transcripts from the inventors’ CRISPRa (FIG. 2B). However, previous reports have indicated that PPARGC1A is able to create an
[0022] 214865-9395-0642, v. 1 autoregulatory feed forward loop to increase its own expression (Fernandez-Marcos & Auwerx, 2011; Lin et al., 2002; Handschin, 2009), which motivated the inventors to measure the levels of endogenous PPARGC1A. Interestingly, while the cDNA system was unable to cause any increase, and might even repress, endogenous PPARGC1A, the inventors’ CRISPRa system increased transcription of endogenous PPARGC1A (FIG. 2C). Before advancing to further energetic characterization, the inventors validated the transcriptional activation ability of their CRISPRa system in additional cells. Collectively, these results indicated that the inventors’ CRISPRa system can activate transcription of PPARGC1A in human neonatal fibroblasts (HFF), adult fibroblasts (HDF), cardiomyocytes (CM) and rat myoblasts (RM; FIG. 2D). Overall, these data support the inventors’ CRISPRa system as a novel approach to specifically activate mitochondrial biogenesis gene expression in a diverse array of cells. Synthetic expression of nuclear encoded genes leads to mitochondria biogenesis. The inventors observed that activation of PPARGC1A with CRISPRa resulted in an increase in the number of mitochondria relative to control in several human cell types (FIG. 3A). They measured mitochondrial DNA (mtDNA) levels because they serve as a robust proxy for mitochondrial biogenesis (Rooney et al., 2015). Notably, while cDNA overexpression resulted in higher total levels of PPARGC1A transcript relative to CRISPRa (FIG. 2B), it did not translate to higher levels of mitochondria in comparison to CRISPRa (FIG. 3A). This could be attributed to an intrinsic advantage of endogenous expression over cDNA expression, as observed previously with CRISPRa (Black et al., 2016; Kwon et al., 2020). Importantly, these levels of synthetically increased mitochondrial DNA were corroborated with fluorescence microscopy utilizing tetramethylrhodamine, ethyl ester (TMRE), a mitochondrial stain (FIG. 3B) (Iannetti et al., 2016; Wolf et al., 2019). These results demonstrate that the targeted synthetic expression of PPARGC1A, a key endogenous nuclear encoded gene, is sufficient to increase mitochondria quantity in human cells. Engineered increases in cellular mitochondria are functionally beneficial for human cardiomyocytes. To establish whether the synthetic induction of endogenous mitochondria biogenesis through CRISPRa led to enhanced mitochondrial function, the inventors delivered CRISPRa targeting PPARGC1A to human CMs (AC16) and assessed mitochondrial functionality by measuring the cellular oxygen consumption rate (OCR) (Chance & Williams, 1955; Divakaruni & Jastroch, 2022). They observed that activation of PPARGC1A with CRISPRa led to a marked increase in OCR relative to both cDNA and WT control (63% and 135%, respectively) in CMs (FIG. 4A). They also detected a large increase in ATP
[0023] 224865-9395-0642, v. 1 production (FIG. 4B), and maximal respiration (FIG. 4C). These results indicate that the mitochondria induced by CRISPRa enhance CM energetics. Moreover, CRISPRa leads to a higher bioenergetic enhancement than conventional cDNA overexpression strategies. These data collectively demonstrate that the inventors can robustly stimulate mitochondrial biogenesis and improve mitochondrial function using the synthetic activation of nuclear encoded genes in human cardiomyocytes, thus obviating the need for mitochondrial isolation and storage. The simultaneous engineered activation of multiple genes can enhance mitochondria biogenesis in human cells. Although PPARGC1A is considered the master regulator of mitochondria biogenesis, other genes, such as PPARGC1B (also known as 3*&^ȕ), NRF2, and TFAM are also important canonical regulators of mitochondria biogenesis (Scarpulla, 2011; Scarpulla, 2008; Villena, 2015). Therefore, the inventors hypothesized that combinations of these factors would synergize in the context of mitochondrial biogenesis. Leveraging the inventors’ expertise with multiplexed CRISPRa in human cells (FIG.5A) (Kabadi et al., 2014; Mahata et al., 2022), they tested this hypothesis by simultaneously activating two canonical regulators of mitochondria biogenesis: PPARGC1A and PPARGC1B, because these two genes often drive biogenesis in differing yet converging manners (Scarpulla, 2008; St-Pierre et al., 2013). These results demonstrated that activation of either PPARGC1A or PPARGC1B resulted in an increase in mitochondria (FIG. 5B), and fascinatingly, that activation of both PPARGC1A and PPARGC1B with CRISPRa resulted in a higher number of mitochondria than either alone (FIG.5B). However, in contrast the inventors found that cDNA expression of both PPARGC1A and PPARGC1B resulted in fewer mitochondria (FIG. 5B), potentially due to deleterious supraphysiological overexpression (Lehman et al., 2000; Russell et al., 2004; Ciron et al., 2012; Zhu et al., 2019; Bonekamp et al., 2021). CRISPRa screening can be used to uncover novel drivers of complex cell behaviors. The inventors previously showed that CRISPRa can be used to selectively activate diverse human pathways by targeting virtually any endogenous gene (Hilton et al., 2015; Li et al., 2021; Wang et al., 2022; Mahata et al., 2022). This targeting versatility is due to the high frequency of gRNA target sites available in the human and murine genomes (especially for SaCas9 and SpCas9) (Klann et al., 2017; Li et al., 2021; Gilbert et al., 2014; Concordet & Haeussler, 2018; Sanson et al., 2018; Doench, 2018; Sanjana et al., 2014; Montalbano et al., 2017; Kamber et al., 2021). The inventors and others have leveraged this targeting range, as well as the ease with which gRNAs can be synthesized and delivered via lentiviral vectors, to use CRISPRa to screen
[0024] 234865-9395-0642, v. 1 for complex cellular phenotypes in high throughput (Klann et al., 2017; Li et al., 2021; Gilbert et al., 2014; Concordet & Haeussler, 2018; Sanson et al., 2018; Doench, 2018; Sanjana et al., 2014; Montalbano et al., 2017; Kamber et al., 2021; Horlbeck et al., 2016; Hill et al., 2018). For instance, the inventors recently developed a novel CRISPRa tool (called dCas9-dMSK1) and used this engineered biomolecule in combination with high-throughput screening to identify novel drivers of therapeutic resistance in human melanoma cells (FIG.6) (Li et al., 2021). They have also previously used CRISPRa screening to probe how the noncoding genome controls human gene expression (Klann et al., 2017). Importantly, in each of these examples the gRNA libraries the inventors used were orders of magnitude larger than those the inventors propose here. Therefore, they have very high confidence that one can utilize CRISPRa to identify and quantify how non-canonical genes and cellular pathway members drive mitochondrial biogenesis and function. To this end, the inventors plan to activate non-canonical regulators of mitochondria biogenesis in AC16 cells and enrich / select for gene products that act as strong inducers of this phenotype. In addition to the gRNAs targeting the 6 associated pathways previously mentioned (FIG. 7), they will include gRNAs targeting the canonical mitochondria biogenesis pathway, including PPARGC1A, PPARGC1B, TFAM, and NRF2 as positive controls, and 10 non- targeting gRNAs as negative controls. The inventors’ custom library targets a total of 329 unique non-canonical human genes, with 3 different gRNAs for each gene (for statistical power and validation purposes), for a total of 987 gRNAs. These gRNAs have been carefully curated from previously validated genome-wide CRISPRa screens (Klann et al., 2017; Li et al., 2021; Konermann et al., 2015). This gRNA library will be cloned into a lentivirus backbone encoding the inventors’ CRISPRa system along with a single gRNA from the library (i.e., each CRISPRa lentivirus will also encode only one gRNA), similar to the inventors’ previous work (Klann et al., 2017; Li et al., 2021). 72 hours post-transduction of lentiviral libraries into human cardiomyocyte AC16 cells, cells will be stained with MitoTracker and sorted using fluorescence-activated cell sorting (FACS) (Saha et al., 2022). The inventors will isolate the top 10% highest fluorescing cells, as a proxy indicator of the highest mitochondria biogenesis induction relative to wildtype cells (FIG. 7). DNA from sorted cells will then be extracted and gRNA sequences will be identified using next generation sequencing (NGS) as they and others have done previously (Klann et al., 2017; Li et al., 2021; Konermann et al., 2015). Gene ontology and pathway analysis will be performed using the R package clusterProfiler (Yu et al., 2012). Protein-protein interaction analysis will be performed using the R package
[0025] 244865-9395-0642, v. 1 STRINGdb (Szklarczyk et al., 2020). The inventors will validate the top 10 library-identified non-canonical target genes that highly enhance mitochondria biogenesis using low-throughout lentiviral transduction followed by evaluating changes in mitochondria quantity and mitochondria function utilizing qPCR and respirometry in CMs (AC16 and patient-derived cells). Finally, the inventors will assess the therapeutical benefit of the top 3 novel CRISPRa targets in a cardiac context. This will be achieved by delivering these gRNAs and CRISPRa (via lentivirus) into patient-derived cells. 72 hours post-transduction, they will assess mitochondrial quantity and function utilizing qPCR and respirometry, as described above. Tunable control of mitochondria biogenesis maintains cellular migration rate while averting negative effects from cDNA overexpression systems. In order to establish and quantify the functional changes resulting from engineered mitochondrial biogenesis, the inventors delivered CRISPRa targeting PPARGC1A to mesenchymal stem cells (MSCs) and assessed the changes in cell migration caused by increased mitochondria quantity using a scratch assay (Liang et al., 2007). The inventors imaged the cells every hour over a 36-hour period (FIG. 8A). After scratch injury, CRISPRa targeting PPARGC1A and cDNA overexpression of PPARGC1A result in similar coverage of the wound area begin cause the MSCs to migrate into the wound area, however 24 hours after scratching, CRISPRa treatment allows MSCs to cover wound area to similar levels as WT control (FIG. 8B). Deriving the rate of wound closure for each treatment reveals that CRISPRa treatment marginally increases the rate of cell migration in comparison to WT control, whereas cDNA treatment noticeably decreases the rate of cell migration in comparison to WT control (FIG.8C). While these results are in line with previous studies showing that increased mitochondria quantity improves cell migration (Levoux et al., 2021), the inventors’ preliminary data also indicates that the increment in mitochondria quantity requires precise tuning and control to result in beneficial effects, as excessive levels of mitochondria can be detrimental to additional cell functions. HF is driven by a deficit of mitochondria. Reduction of mitochondrial content and function are major sequelae of MI pathogenesis, leading to HF. A promising solution to revert this pathology is increasing the number of mitochondria in the heart. The inventors hypothesize that synthetic expression of nuclear encoded genes leads to mitochondrial biogenesis and improves myocardial viability and function in HF. CRISPRa is often superior to conventional overexpression strategies. CRISPRa is a novel system to activate the transcription of endogenous genes and control multi-gene expression simultaneously. Additionally, CRISPRa enables activation of all isoforms, fine tuning of gene dosage, and subsequent incorporation of
[0026] 254865-9395-0642, v. 1 post-translational modifications, which can improve efficacy (FIG. 4) and potentially prevent adverse effects seen with conventional cDNA strategies. Canonical mitochondrial biogenesis pathways are valuable therapeutic targets. As PPARGC1A is considered the master regulator of mitochondria biogenesis, the inventors initially applied CRISPRa towards its activation and observed enhanced mitochondrial biogenesis and function in multiple cell types including human CMs (FIGS. 3 and 4; AC16 cells). Other canonical genes, such as PPARGC1B, NRF2, and TFAM are also known to be critical regulators of mitochondria biogenesis, yet have been underexplored as potential therapeutic targets in HF. Consequently, inventors will systematically evaluate these genes singularly or in combinations and evaluate pathway interactions to determine if therapy can be optimized relative to PPARGC1A alone. Wound healing is driven by mitochondrial activity. Mitochondria are critical elements in the wound healing process, not only the provide the energy needed for wound healing processes such as cell proliferation and differentiation, but to generate major signaling metabolites during wound healing. Given this critical role, the inventors hypothesize that synthetic expression of nuclear encoded genes leads to mitochondrial biogenesis and improves cellular bioenergetic and wound healing. CRISPRa is often superior to conventional overexpression strategies. CRISPRa is a novel system to activate the transcription of endogenous genes and control multi-gene expression simultaneously. Additionally, CRISPRa enables activation of all isoforms, fine tuning of gene dosage, and subsequent incorporation of post-translational modifications, which can improve efficacy (FIG. 4) and potentially prevent adverse effects seen with conventional cDNA strategies. Canonical mitochondrial biogenesis pathways are valuable therapeutic targets. As PPARGC1A is considered the master regulator of mitochondria biogenesis, the inventors initially applied CRISPRa towards its activation and observed enhanced mitochondrial biogenesis and function in multiple cell types including human fibroblasts (FIGS. 3 and 4; HDF cells). Other canonical genes, such as PPARGC1B, NRF2, and TFAM are also known to be critical regulators of mitochondria biogenesis, yet have been underexplored as potential therapeutic targets. Consequently, the inventors will systematically evaluate these genes singularly or in combinations and evaluate pathway interactions to determine if therapy can be optimized relative to PPARGC1A alone. * * * * * * * * * * * * * * * * * All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the
[0027] 264865-9395-0642, v. 1 compositions and methods of this disclosure have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the disclosure. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the disclosure as defined by the appended claims.
[0028] 274865-9395-0642, v. 1 VI. References The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference. Ali Pour et al., Journal of the American Heart Association 9, e014501 (2020). Baar et al., The FASEB Journal 17, 1666–1673 (2003). Balboa et al., Stem Cell Reports 5, 448–459 (2015). Benjamin et al., Circulation 139, (2019). Bensley & Hoerr, The Anatomical Record 60, 449–455 (1934). Black et al., Cell Stem Cell 19, 406–414 (2016). Braunschweig et al., Europace 13 Suppl 2, ii13-17 (2011). Brown et al., J Cardiovasc Pharmacol Ther 19, 121–132 (2014). Brown et al., Nat Rev Cardiol 14, 238–250 (2017). Bonekamp et al., Life Science Alliance 4, (2021). Cowan et al., PLoS One 11, e0160889 (2016). Chatfield et al., JACC Basic Transl Sci 4, 147–157 (2019). Chance & Williams, Nature 175, 1120– 1121 (1955). Chavez et al., Nature Methods 12, 326– 328 (2015). Ciron et al., Hum Mol Genet 21, 1861–1876 (2012). Concordet & Haeussler, Nucleic Acids Research 46, W242–W245 (2018). Daubert et al., Circ Heart Fail 10, e004389 (2017). De Virgilio et al., Mitochondrion 11, 287–295 (2011). Divakaruni & Jastroch, Nat Metab 4, 978–994 (2022). Doench, Nat Rev Genet 19, 67–80 (2018). Dominy & Puigserver, Cold Spring Harb Perspect Biol 5, a015008 (2013). Doughty et al., J Am Coll Cardiol 23, 814–821 (1994). Doulamis et al., Eur J Cardiothorac Surg 57, 836–845 (2020). Escobar et al. ACS Synth. Biol. (2022). Emani et al., The Journal of Thoracic and Cardiovascular Surgery 154, 286–289 (2017). Fernandez-Marcos & Auwerx, The American journal of clinical nutrition 934, 884S–90 (2011). Finck & Kelly, The Journal of clinical investigation 1163, 615–22 (2006).
[0029] 284865-9395-0642, v. 1 Garbern & Lee, Stem Cell Res Ther 12, 177 (2021). Garcia-Roves et al., Proceedings of the National Academy of Sciences 104, 10709–10713 (2007). Gemberling et al., Nat Methods 18, 965–974 (2021). Gilbert et al., Cell 154, 442–451 (2013). Gilbert et al., Cell 159, 647–661 (2014). Goell & Hilton,Trends Biotechnol 39, 678–691 (2021). Gohil & Greenberg, Journal of Cell Biology 184, 469–472 (2009). Guerra-Resendez & Hilton, Methods Mol Biol 2518, 237–251 (2022). Guariento et al., The Journal of Thoracic and Cardiovascular Surgery 162, 992–1001 (2021). Gureev et al., Frontiers in Genetics 10, (2019). Gurtner et al. Nature 453, 314–321 (2008). Handschin, Trends in pharmacological sciences 306, 322–9 (2009). Heden et al., Trends in Endocrinology & Metabolism 27, 553–562 (2016). Heidenreich et al., Circ Heart Fail 6, 606–619 (2013). Hill et al., Nat Methods 15, 271–274 (2018). Hilton et al., Nature Biotechnology 33, 510–517 (2015). Hilton & Gersbach, Genome Res 25, 1442–1455 (2015). Horlbeck et al., eLife 5, e19760 (2016). Hubbard et al., Sci Rep 9, 9656 (2019). Iannetti et al., Nat Protoc 11, 1693–1710 (2016). Ikeuchi et al., Circulation 112, 683–690 (2005). Jornayvaz & Shulman, Essays Biochem 47, 10.1042 / bse0470069 (2010). Kabadi et al., Nucleic Acids Res 42, e147 (2014). Kajstura et al., Proc Natl Acad Sci USA 95, 8801–8805 (1998). Kamber et al. Nature 597, 549–554 (2021). Kaza et al., J Thorac Cardiovasc Surg 153, 934–943 (2017). Kelly & Scarpulla, Genes & development 184, 357–68 (2004). Khan et al., Free Radic Biol Med 116, 159–171 (2018). Khoshandam et al., Genes & Diseases 11, 268–282 (2024). Klann et al., Nature Biotechnology 35, 561–568 (2017). Klyubin et al., Eur J Cell Biol 70, 347–351 (1996).
[0030] 294865-9395-0642, v. 1 Knighton, D. R. et al., Science 221, 1283–1285 (1983). Konermann et al., Nature 517, 583–588 (2015). Kwon et al., Stem Cell Reports 14, 755–769 (2020). Lagouge et al., Cell 127, 1109–1122 (2006). Lanza et al., Cell Metabolism 16, 777–788 (2012). Lee et al., Sci Adv 6, eaba1773 (2020). Lefterova & Lazar, Trends in Endocrinology & Metabolism 20, 107–114 (2009). Lehman et al., J Clin Invest 106, 847–856 (2000). Levoux et al., Cell Metabolism 33, 283-299.e9 (2021). Li et al., Nat Commun 12, 896 (2021). Li et al., Sig Transduct Target Ther 8, 1–23 (2023). Liang et al., Nat Protoc 2, 329–333 (2007). Lightowlers et al., EMBO Rep.21, e50964 (2020). Lin et al., Nature 418, 797–801 (2002). Lin et al., Cell metabolism 16, 361–70 (2005). Lopaschuk et al., Physiol Rev 90, 207–258 (2010). Lopaschuk et al., Circ Res 128, 1487–1513 (2021). Lowell & Spiegelman, Nature 404, 652–660 (2000). Madigan et al., Nat Rev Drug Discov 1–20 (2023). Magyar et al., Clin Hemorheol Microcirc 50, 179–187 (2012). Mahata et al. biorxiv.org / lookup / doi / 10.1101 / 2022.03.21.485228 (2022) Maniura-Weber et al., Nucleic Acids Research 32, 6015–6027 (2004). Masuzawa et al., Am J Physiol Heart Circ Physiol 304, H966-982 (2013). McCully et al., Am J Physiol Heart Circ Physiol 296, H94–H105 (2009). McCully et al., Mitochondrion 34, 127–134 (2017). McCully et al., Clin. Transl. Med. 5, 16 (2016). Mitschka & Mayr, Nat Rev Mol Cell Biol 23, 779–796 (2022). Montalbano et al., Mol Cell 68, 44–59 (2017). Murphy et al.. Circulation Research 118, 1960– 1991 (2016). Neubauer, N Engl J Med 356, 1140–1151 (2007). Niethammer et al., Nature 459, 996–999 (2009). Nisoli et al., Am J Cardiol 101, 22E- 25E (2008). Nisoli et al., Science 310, 314–317 (2005).
[0031] 304865-9395-0642, v. 1 Ploumi et al., The FEBS Journal 284, 183–195 (2017). Piantadosi et al., Circ Res 103, 1232–1240 (2008). Puigserver et al., Cell 92, 829–839 (1998). Qi et al. Cell 152, 1173–1183 (2013). Ragni et al. Frontiers in Neuroscience 17, (2023). Ritterhoff & Tian, Nat Rev Cardiol (2023). Rodriguez et al., Dermatol Surg 34, 1159–1169 (2008). Rosca et al., Cardiovasc Res 80, 30–39 (2008). Rooney et al., Methods Mol Biol 1241, 23–38 (2015). Russell et al. Circulation Research: Journal of the American Heart Association 94, 525–533 (2004). Sabbah et al. Circulation: Heart Failure 9, e002206 (2016). Saha et al., Nat. Nanotechnol. 17, 98–106 (2022). Sanson et al., Nat Commun 9, 5416 (2018). Sanjana et al., Nature Methods 11, 783–784 (2014). Scarpulla, Biochimica et biophysica acta 18137, 1269–78 (2011). Scarpulla, Physiol Rev 88, 611–638 (2008). Sen, C. K. et al. J Biol Chem 277, 33284–33290 (2002). Shi et al., PLoS One 8, e54054 (2013). Shin et al., JACC Basic Transl Sci 4, 871–888 (2019). Sims Journal of Neurochemistry 55, 698–707 (1990). Singh et al., Cell Death Dis.9, 1–14 (2018). St-Pierre et al., J. Biol. Chem.278, 26597–26603 (2003). Solovieff et al., Nat Rev Genet 14, 483–495 (2013). SOLVD Investigators et al., N Engl J Med 325, 293–302 (1991). Soneja, A., Drews, M. & Malinski, T., Pharmacol Rep 57 Suppl, 108–119 (2005). Soonpaa & Field, Circ Res 83, 15–26 (1998). Sun et al., Molecular Cell 61, 654–666 (2016). Sung & Dyck, Annals of the New York Academy of Sciences 1348, 32–45 (2015). Sung et al., Circ Heart Fail 8, 128–137 (2015). Suomalainen & Battersby, Nat Rev. 19: 77-92 (2018). Szklarczyk et al., Nucleic Acids Res 49, D605–D612 (2020).
[0032] 314865-9395-0642, v. 1 Taegtmeyer & Lubrano, F1000Prime Rep 6, 90 (2014). Thakore et al., Nature Methods 13, 127–137 (2016). Tian et al., Circulation 140, 1205–1216 (2019). Ting et al., Science 308, 411–413 (2005). Tyson et al., Nat Rev Mol Cell Biol 2, 908– 916 (2001). Uhlén et al., Science 347, 1260419 (2015). Valerio et al., Aging (Albany NY) 3, 464–478 (2011). van Tienen et al., Journal of Cellular Biochemistry 111, 1575–1585 (2010). Velagaleti et al., Circulation 118, 2057–2062 (2008). Villena, FEBS J 282, 647–672 (2015). Walle et al., Drug Metab Dispos 32, 1377–1382 (2004). Wang et al., Nature 456, 470–476 (2008). Wang et al., J Food Sci 79, H1823-1831 (2014). Wang et al., Sci Transl Med 8, 326rv3 (2016). Wang et al., Nucleic Acids Res 50, 7842–7855 (2022). Wilcox et al., JACC Heart Fail 3, 661–669 (2015). Wolf et al., EMBO J 38, e101056 (2019). Wu et al., Cell 98, 115–124 (1999). Yu et al., OMICS 16, 284–287 (2012). Zhao et al., J Am Chem Soc 145, 413–421 (2023). Zhou & Tian, Journal of Clinical Investigation 128, 3716–3726 (2018). Zhu et al., Circulation Research 125, 707–719 (2019). Zordoky et al., Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1852, 1155–1177 (2015). U.S. Patent Publication 20200181578A1 EP3851112A1 EP3169338A1 US Patent Publication 20200239850A1 US Patent Publication 20110008310A1 US Patent Publication 20190134088A1 US Patent 9855296 PCT / US23 / 61620
[0033] 324865-9395-0642, v. 1
Claims
WHAT IS CLAIMED IS:
1. A method of increasing mitochondria in a cell or increasing mitochondrial activity in a cell comprising introducing into said cell fusion protein comprising a DNA-binding protein (DBP) construct fused to a transcriptional regulator that modulates endogenous mitochrondrial gene expression.
2. The method of claim 1, wherein the fusion protein modulates expression of one or more of PPARGC1A, PPARGC1B, NFE2L2, NRF1, TFAM genes, TFB2M, NRF2, SRIT1, GSK3B, or KEAP1.
3. The method of claim 1, wherein the DBP is a Cas9, such as dCas9, such as Staphylococcus aureus dCa9 (SadCas9), or a zinc finger DBP, or a TALE.
4. The method of any one of claims 1-3, wherein the DBP is Cas9, such as dCas9, such as Staphylococcus aureus dCa9 (SadCas9), wherein the transcriptional regulator is a transactivator such as VP64, or a transcriptional repressor, such as a KRAB domain or DNA methyl transferase domain.
5. The method of claim 4, wherein the SadCa9 fusion to VP64 is further fused to eNRF2- MRTF-A-STAT1 (NMS) transcriptional activation domains, such as wherein the 5’ to 3’ configuration of elements is NMS-SadCa9-VP64.
6. The method of claim 1, wherein PPARGC1A and NRF1 genes, PPARGC1A and TFAM genes, NRF1 and TFAM genes, PPARGC1A and PPARGC1B genes, PPARGC1B and NRF1 genes, PPARGC1B and TFAM genes, PPARGC1A, NRF1 and TFAM genes, PPARGC1A, PPARGC1B, and TFAM genes, PPARGC1A, PPARGC1B, and NRF1 genes or PPARGC1A, PPARGC1B, NRF1 and TFAM genes are targeted and activated.
7. The method of any on one of claims 1-6, wherein the DBP is a Cas9, such as dCas9, and a gRNA targeting sequence is included, such as selected from: CRISPR Target gRNA Sequence SadCas9 PPARGC1A 1 ATGCTGTGATTAAAGCCAGCTTTGAAT (SEQ ID NO:334865-9395-0642, v. 1SadCas9 PPARGC1A 2 CACTGAAGCAGAGGGCTGCCTTTGAGT (SEQ ID NO: 2) SadCas9 PPARGC1A 3 GGGCTGCCTTTGAGTGACGTCACGAGT (SEQ ID NO: 3) SadCas9 PPARGC1A 4 GCACAGGGGAAGGGAGGCTGGGTGAGT (SEQ ID NO: 4) AsdCas12a PPARGC1A 1 TTTAAAGCGTTACTTCACTGAAGCAGA (SEQ ID NO: 5) AsdCas12a PPARGC1A 2 TTTGAGTGACGTCACGAGTTAGAGCAG (SEQ ID NO: 6) AsdCas12a PPARGC1A 3 TTTAATAGCTTTGTCATGTGACTGGGG (SEQ ID NO: 7) AsdCas12a PPARGC1A 4 TTTGTCATGTGACTGGGGACTGTAGTA (SEQ ID NO: 8) EnAsdCas12a PPARGC1A 1 TGTAGTAAGACAGGTGCCTTCAGTTCA (SEQ ID NO: 9) SadCas9 PPARGC1B 1 CAGCTCACGCAGCCCTCAGCAAGGGGT (SEQ ID NO: 10) SadCas9 PPARGC1B 2 CGCCAGACACGGCGCAGGAAAGTGGGT (SEQ ID NO: 11) SadCas9 PPARGC1B 3 CGCGCGGCGCCCGCGGGAGCCGGGGGT (SEQ ID NO: 12) SadCas9 PPARGC1B 4 CGAGCAAGGGAGGAGGGAGGAGGGAGT (SEQ ID NO: 13) SadCas9 TFAM 1 GCCAGAGCCCTCCGCAGGCTAGAGGAT (SEQ ID NO: 14) SadCas9 TFAM 2 CGGTGGGCGGCCTTGCGGGGGAGGAAT (SEQ ID NO: 15) SadCas9 TFAM 3 CTCCCCCGCAAGGCCGCCCACCGGGGT (SEQ ID NO: 16) SadCas9 TFAM 4 CGCCCCGCCCCCATCTACCGACCGGAT (SEQ ID NO: 17) SadCas9 NRF1 1 GGGCCGGAACCTCAAAAGCAACTGGAT (SEQ ID NO: 18) SadCas9 NRF1 2 TCCGTGCACGCGACGCGGCGGCGGGGT (SEQ ID NO:344865-9395-0642, v. 1AsdCas12a NRF1 1 TTTGGAGGGGGCCGGAACCTCAAAAGC (SEQ ID NO: 20 AsdCas12a NRF1 2 TTTGAGGTTCCGGCCCCCTCCAAACCT (SEQ ID NO: 21) EnAsdCas12a NRF1 1 TGTGCTGCGGGCAGGCAGCGGAGAGGG (SEQ ID NO: 22) EnAsdCas12a NRF1CTTCCCCGCCCGGCCGCCGCCATGATG (SEQ ID NO: 23).
8. The method of any one of claims 1-7, wherein the DBP construct is delivered to said cell in an integrative vector or non-integrating vector, such as an adeno-associated viral vector or a non-integrating lentiviral vector.
9. The method of any one of claims 1-7, wherein the DBP construct is delivered to said cell in a non-viral vector, such as a lipid nanoparticle, by electroporation, or by microinjection.
10. The method of claims 1-9, wherein the cell is an isolated cell treated ex vivo and subsequently administered to a living subject.
11. The method of any one of claims 1-9, wherein the cell is located in a living subject.
12. The method of claim 10 or claim 11, wherein the living subject suffers from a disease or disorder characterized by mitochondrial dysfunction.
13. The method of claim 12, wherein the disease or disorder is cardiovascular disease, a respiratory disease, a musculoskeletal disease, a reproductive disease, a digestive disease, or a neuromuscular disease.
14. The method of claim 10 or claim 11, wherein the subject suffers from a disease, disorder or injury for which improved mitochondrial function would be therapeutic, or wherein the subject does not suffer from a disease, disorder or injury for which improved mitochondrial function would be therapeutic and is treated to improve normal bioenergetics.
15. The method of claim 14, wherein the disease, disorder or injury is a wound.354865-9395-0642, v.
116. A nucleic acid construct encoding a fusion protein comprising a DNA-binding protein (DBP) construct fused to a transcriptional regulator.
17. The nucleic acid construct of claim 16, wherein the DBP is a Cas9, such as dCas9, such as Staphylococcus aureus dCa9 (SadCas9), or a zinc finger DBP, or a TALE.
18. The nucleic acid construct of claim 16, where the construct comprises, in a 5’ to 3’ order, coding sequences for (a) eNRF2-MRTF-A-STAT1 (NMS) transcriptional activation domains, (b) SadCas9, and (c) VP64.
19. The nucleic acid construct of claim 16, wherein the nucleic acid construct (a) is in an integrative vector or non-integrating vector, such as an adeno-associated viral vector or a non- integrating lentiviral vector, or (b) is in a non-viral vector, optionally formulated for delivery in a lipid nanoparticle, by electroporation, or by microinjection.
20. A fusion protein comprising a DNA-binding protein (DBP) construct fused to a transcriptional regulator that modulates endogenous mitochondrial gene expression.
21. The fusion protein of claim 20, wherein the fusion protein modulates expression of one or more of PPARGC1A, PPARGC1B, NFE2L2, NRF1, TFAM genes, TFB2M, NRF2, SRIT1, GSK3B, or KEAP1.
22. The fusion protein of claim 20 or claim 21, wherein the DBP is dCas9, such as Staphylococcus aureus dCa9 (SadCas9), or a zinc finger DBP, or a TALE.
23. The fusion protein any one of claims 20-22, wherein the DBP is dCas9, such as Staphylococcus aureus dCa9 (SadCas9), wherein the transcriptional regulator is a transactivator, such as VP64, or a transcriptional repressor, such as a KRAB domain or DNA methyl transferase domain.
24. The fusion protein of claim 23, wherein the SadCa9 fusion to VP64 is further fused to eNRF2-MRTF-A-STAT1 (NMS) transcriptional activation domains, such as wherein the 5’ to 3’ configuration of elements is NMS-SadCa9-VP64.
25. A kit comprising nucleic acid construct according to any one of claims 16-19.364865-9395-0642, v.
126. The kit according to claim 25, wherein the DBP is dCas9 or SadCas9 and the kit further comprise one or more guide RNA (gRNA) that targets dCas9 or SadCas 9 to one or more of PPARGC1A, PPARGC1B, NFE2L2, NRF1 and TFAM genes, TFB2M, NRF2, SRIT1, GSK3B, or KEAP1, and even further optionally including receptacles to contain the nucleic acid construct, gRNAs, packaging to hold said receptacles, and / or instructions for use.374865-9395-0642, v. 1
